Join
Live feed
·
PRReleasevia Quantisnow
REGENXBIO Inc. logo

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

ByQuantisnow·Wall Street's wire, on your screen.
RGNX· REGENXBIO Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RGNX (REGENXBIO Inc.) and more on Quantisnow.